Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available

Exclusion Criteria

• •1. Received chemotherapy or therapeutic radiotherapy 28 days prior to the first dose of study medication or has ongoing side effects ≥ grade 2 due to agents administered more than 28 days earlier.
• •2. Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring parenteral antibiotics; symptomatic congestive heart failure; unstable angina pectoris, angioplasty, stenting, or myocardial infarction 6 months prior to the first dose of study medication; uncontrolled hypertension; clinically significant cardiac arrhythmia including but not limited to: multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia; uncontrolled diabetes; psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
• •3. Progressive or symptomatic brain metastases
• •4. Has a serious or nonhealing active wound, ulcer, or bone fracture.
• •5. Known human immunodeficiency virus positivity.
• •6. Major surgical procedure, an open biopsy, or a significant traumatic injury 28 days prior to treatment.
• •7. Is currently or has recently used (28 days prior to) a thrombolytic agent.
• •8. Currently using full-dose warfarin (an exception is low-dose warfarin to maintain patency of pre-existing, permanent, indwelling intravenous \[I.V.\] catheters; for patients receiving warfarin, the international normalized ratio \[INR\] should be \< 1.5). A patient requiring heparin is excluded.
• •9. Undergoes chronic daily treatment with aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function (cyclooxygenase-2 \[COX-2\] inhibitors are permitted).
• •10. Has a history or clinical evidence of a deep venous or arterial thrombosis (including pulmonary embolism) 6 months prior to the first dose of study medication.
• •11. Has proteinuria ≥ 2+ by routine urinalysis
• •12. Pregnancy (confirmed by serum beta human chorionic gonadotropin) or lactating
• •13. Received prior treatment with agents targeting the PDGFR ligand or receptor 6 weeks prior to the first dose of study medication.
• •14. Received prior treatment with monoclonal antibodies 6 weeks prior to the first dose of study medication.
• •15. Has a history of allergic reactions to monoclonal antibodies or other therapeutic proteins.